The US Food and Drug Administration (FDA) has announced that starting on 1 October 2026, manufacturers must submit adverse event individual case safety reports (ICSRs) for drugs, biologics, and ...
The US Food and Drug Administration (FDA) has finalized guidance that spells out how generic drug manufacturers can electronically submit expedited individual case safety reports (ICSRs) for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results